Torrent Investments, a promoter entity of Torrent Pharmaceuticals, has offloaded a total of 99.44 lakh shares or 2.94 per ...

The company continues to prioritize its pipeline development, with expectations for further advancements in clinical trials for its CNS product candidates. Looking ahead, Supernus Pharmaceuticals aims ...

Total revenues were $175.7 million in the third quarter of 2024, an increase of 14% compared to the same period in 2023. Total revenues excluding Trokendi XR ® and Oxtellar XR ® net product sales (non ...

CNS Pharmaceuticals (NASDAQ: CNSP) , focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in ...

Detailed price information for Cns Pharmaceuticals Inc (CNSP-Q) from The Globe and Mail including charting and trades.

Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) is scheduled to be announcing its earnings results after the market closes on Monday, November 4th. Analysts expect the company to announce ...

CNS Pharmaceuticals (NASDAQ: CNSP) announced that it received an exception from the nasdaq Hearings Panel, granting the company until March 11, 2025, to meet the minimum bid price requirement under ...

"The FDA's approval of Lumryz was not arbitrary or capricious," U.S. District Judge Amit P. Mehta wrote in a memorandum ...

HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a ...

Q3 2024 Earnings Call Transcript October 31, 2024 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.87, expectations were $-0.93. Operator: Good day, everyone, and welcome ...

CNS Pharmaceuticals (CNSP) announced that on October 30, 2024, it received notice from The Nasdaq Hearings Panel that the Company has been ...